12/02/2021
Challenges in the Detection of Metabolic Biomarkers Using a Multi Plex Assay
In the work we present to the 14th EBF Open Symposium, we show a 5 Plex method for the detection of metabolic biomarkers in human plasma was developed using the U-PLEX technology on the MSD platform.
The complexities surrounding this method were the establishment of endogenous QCs for each chosen biomarker and evaluating the potential use and need for buffer QCs vs matrix QCs where applicable. Additional challenges were faced while trying to ascertain a single minimum required dilution to enable accurate quantification of all biomarkers simultaneously, encompassing the different detection ranges and limits for each biomarker.
The method development focused on the challenges of balancing the detection of the 5 biomarkers; ensuring that each could be quantified within its own required range whilst maintaining a method that was fit for purpose for all 5 biomarkers. To enable this balance, the context of use for each biomarker was evaluated and the method adapted as required.
A fit for purpose method was established that met the requirements for the need and context of use. The method was used successfully in the quantification of human samples from a clinical study.
You may find below the poster for your ready reference:
MORE NEWS
Anapharm Bioanalytics Brazilian ANVISA Certificate Renewal
Anapharm Bioanalytics is proud to announce that it has recently renewed its ANVISA (Brazil) certification which is now valid until February 26th, 2026.
Anapharm Bioanalytics Secures Funding from Eurostars and CDTI for Innovative Project on Therapy and Diagnosis of Ewing Sarcoma
Barcelona, April 18th, 2023 – Anapharm Bioanalytics, a leading bioanalytical contract research organization (CRO), is delighted to announce the successful acquisition of funding from the Eurostars-3 joint program, with co-funding from CDTI (Centre for Industrial Technological Development) and the European Union’s Horizon Europe Research and Innovation Framework. This funding marks a significant milestone for the groundbreaking project, a collaborative effort between Anapharm Bioanalytics, iCellate Medical, and Aptadel Therapeutics.
Challenges in the Development of a Method for the Detection of Anti-PEGylated-aptamer Antibodies
Immunogenicity assays capable of properly determining the presence of anti-drug antibodies (ADA) and anti-PEG antibodies have been recognized of great importance due to the fact that pre-existing anti-PEG antibodies could have an impact on the efficacy of a drug coupled to polyethylene glycol (PEG).